 <h1>Ziagen Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>abacavir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about abacavir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ziagen.</p><h2>In Summary</h2><p><b>Common side effects of Ziagen include:</b> arthralgia, cough, fatigue, lethargy, myalgia, pruritus, vomiting, chills, and malaise. <b>Other side effects include:</b> hypersensitivity condition, pharyngitis, and tachypnea.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to abacavir: oral solution, oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet; Solution)</p><p>Serious hypersensitivity reactions has been reported. Risk for experiencing a hypersensitivity reaction to abacavir is increased in patients carrying the HLA-B*5701 allele. Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. Screening for the HLA-B*5701 allele is required prior to abacavir initiation and when reinitiating therapy in patients with an unknown HLA-B*5701 status who have previously tolerated abacavir. Discontinue abacavir and do not restart if a hypersensitivity reaction is suspected or cannot be ruled out..</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, abacavir (the active ingredient contained in Ziagen) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking abacavir:</p><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficult or labored breathing</li>
<li>fever</li>
<li>headache</li>
<li>joint or muscle pain</li>
<li>nausea</li>
<li>numbness or tingling of the hands, feet, or face</li>
<li>redness and soreness of the eyes</li>
<li>skin rash</li>
<li>sore throat</li>
<li>sores in the mouth</li>
<li>swelling of the feet or lower legs</li>
<li>unusual feeling of discomfort or illness</li>
<li>unusual tiredness</li>
<li>vomiting</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach swelling</li>
<li>decreased appetite</li>
<li>fast, shallow breathing</li>
<li>sleepiness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chest pain or discomfort</li>
<li>chills</li>
<li>dark urine</li>
<li>itching</li>
<li>light-colored stools</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>red, irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>sweating</li>
<li>unusual weakness</li>
<li>upper right abdominal or stomach pain</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of abacavir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Headache</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Trouble sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Breast enlargement</li>
<li>buffalo hump</li>
<li>central obesity</li>
<li>facial wasting</li>
<li>gaining weight around your neck, upper back, breast, face, or waist</li>
<li>peripheral wasting</li>
</ul><p>
<!-- end oral solution, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to abacavir: oral solution, oral tablet</i></p><h3>General</h3><p>In 1 study, patients receiving the once-daily regimen had a significantly higher incidence of severe drug hypersensitivity reactions and severe diarrhea than patients on the twice-daily regimen.</p>
<p></p>
<p>Many of the side effects listed occurred commonly in patients with abacavir (the active ingredient contained in Ziagen) hypersensitivity (e.g., nausea, vomiting, diarrhea, fever, lethargy, rash).<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity, hypersensitivity reaction (including fever, rash [maculopapular, urticarial], nausea, vomiting, malaise, diarrhea, headache, fatigue, myalgia, achiness, abdominal pain, pharyngitis, dyspnea, cough, lethargy, myolysis, edema, elevated liver function tests, mucous membrane lesions [conjunctivitis, mouth ulceration], sore throat, adult respiratory distress syndrome, respiratory failure, lymphadenopathy, hypotension, anaphylaxis, paresthesia, lymphopenia, hepatitis, liver failure, arthralgia, elevated creatine phosphokinase, elevated creatinine, renal failure, erythema multiforme, abnormal chest x-ray findings [mainly localized infiltrates], death)</p>
<p><b>Frequency not reported</b>: Serious and sometimes fatal hypersensitivity reactions, abacavir (the active ingredient contained in Ziagen) hypersensitivity reaction presenting as acute fibrinous and organizing pneumonia<sup>[Ref]</sup></p><p>Serious and sometimes fatal hypersensitivity reactions have been reported with this drug.  Such reactions have included multi-organ failure and anaphylaxis and usually occurred within the first 6 weeks of therapy (median onset: 9 to 11 days); however, abacavir hypersensitivity reactions have occurred any time during therapy.</p>
<p></p>
<p>Patients with the human leukocyte antigen subtype B*5701 (HLA-B*5701) allele are at higher risk of hypersensitivity reactions to this drug; however, such reactions have occurred in patients without the HLA-B*5701 allele.  Abacavir hypersensitivity was reported in about 8% of patients in 9 clinical trials with abacavir-containing products where patients were not screened for the HLA-B*5701 allele; incidence of suspected abacavir hypersensitivity reactions was 1% in clinical trials where HLA-B*5701 carriers were excluded.</p>
<p></p>
<p>Abacavir hypersensitivity reactions have been characterized by at least 2 of the following key signs/symptoms: (1) fever; (2) rash; (3) gastrointestinal symptoms (including nausea, vomiting, diarrhea, abdominal pain); (4) constitutional symptoms (including generalized malaise, fatigue, achiness); (5) respiratory symptoms (including dyspnea, cough, pharyngitis).  Almost all reactions have included fever and/or rash (usually maculopapular or urticarial); however, reactions also reported without fever or rash.  Signs/symptoms reported in at least 10% of patients with hypersensitivity reaction have included rash, nausea, vomiting, malaise, diarrhea, headache, fatigue/lethargy, abdominal pain, dyspnea, cough, fever, elevated liver function tests, and myalgia.  Other signs/symptoms of hypersensitivity have included mouth ulceration, sore throat, adult respiratory distress syndrome, respiratory failure, edema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, paresthesia, lymphopenia, hepatitis, liver failure, myolysis, arthralgia, elevated creatine phosphokinase, elevated creatinine, renal failure, abnormal chest x-ray findings (mainly infiltrates, which were localized), and death.</p>
<p></p>
<p>Symptoms of abacavir hypersensitivity reaction worsened with continued therapy and generally resolved when this drug was discontinued.  Restarting this drug after a hypersensitivity reaction has resulted in more severe symptoms within hours and included life-threatening hypotension and death.  Rarely, life-threatening reactions have occurred within hours after restarting this drug in patients who stopped it for reasons other than symptoms of hypersensitivity (or who stopped it with only 1 key symptom of hypersensitivity).</p>
<p></p>
<p>In 1 case report, a 57-year-old HIV-positive male presented to medical attention with a 2-day history of fever, malaise, and diarrhea related to initiation of this drug.  Six days prior to the onset of symptoms, the patient's antiretroviral therapy was switched from efavirenz and lamivudine-zidovudine to zidovudine, abacavir, and lopinavir-ritonavir after a drop in his CD4 cell count.  The patient developed acute dyspnea and severe hypoxemia, hemoptysis, and diffuse bilateral pulmonary infiltrates within 72 hours of admission and this drug was discontinued due to suspicion of a hypersensitivity reaction.  Three days after drug discontinuation, the patient's status improved and chest films showed resolution of infiltrates.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Pancreatitis was observed in the expanded access program.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 47%), nausea and vomiting (up to 38%), diarrhea (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain/gastritis/gastrointestinal signs and symptoms, vomiting, abdominal discomfort and pain, abnormal amylase</p>
<p><b>Rare</b> (0.01% to 0.1%): Pancreatitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Malaise and fatigue (up to 34%), temperature regulation disturbance (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Fever/pyrexia, lethargy, fatigue, fatigue/malaise, fever and/or chills</p>
<p><b>Uncommon</b> (0.1% to 1%): Non-site-specific pain</p>
<p><b>Frequency not reported</b>: Asthenia, reduced alcohol tolerance, disulfiram-like reaction<sup>[Ref]</sup></p><p>In 1 case report, a 31-year-old HIV-infected male patient switched to this drug and experienced a disulfiram-like reaction with nausea, facial flushing, and tachycardia after alcohol consumption.  When the patient was rechallenged with a shot of vodka, the same reaction occurred.</p>
<p></p>
<p>In another case, a 27-year-old HIV-infected male patient switched to this drug and noticed reduced alcohol tolerance.  The patient reported that he felt as if he had ingested 1.5 bottles of wine after 3 glasses, with loss of memory until the next morning and vomiting.  The patient was able to tolerate small quantities of alcohol or alcohol consumed with food.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 31%)</p>
<p><b>Common</b> (1% to 10%): Headaches/migraine, dizziness, neuropathy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 24%), ear/nose/throat infections (up to 19%), nasal signs/symptoms (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Viral respiratory infections (including viral ear, nose, and throat infection), bronchitis</p>
<p><b>Frequency not reported</b>: Tachypnea, pharyngitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Elevated creatine phosphokinase (greater than 4 times the upper limit of normal [4 x ULN]) has been reported in up to 8% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated creatine phosphokinase (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Musculoskeletal pain</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Osteonecrosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Suspected Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported during postmarketing experience in patients using this drug primarily in combination with agents known to be associated with SJS and TEN, respectively.</p>
<p></p>
<p>Cases of erythema multiforme, SJS, or TEN have been reported very rarely when abacavir (the active ingredient contained in Ziagen) hypersensitivity could not be ruled out.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Skin rashes (maculopapular, urticarial, or variable appearance; up to 11%)</p>
<p><b>Common</b> (1% to 10%): Rash (without systemic symptoms)</p>
<p><b>Frequency not reported</b>: Sweet's syndrome</p>
<p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypertriglyceridemia (greater than 750 mg/dL), hyperamylasemia (greater than 2 x ULN), and hyperglycemia (greater than 13.9 mmol/L) have been reported in up to 6%, up to 4%, and less than 1% of patients, respectively.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Feeding problems (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Hypertriglyceridemia, hyperamylasemia, anorexia, abnormal triglycerides, hyperlactatemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperglycemia, abnormal alkaline phosphatase, abnormal glucose, abnormal sodium</p>
<p><b>Rare</b> (0.01% to 0.1%): Lactic acidosis</p>
<p><b>Frequency not reported</b>: Mild elevations of blood glucose, hypoglycemia, loss of appetite</p>
<p><b>Postmarketing reports</b>: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Metabolic abnormalities (e.g., hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Dreams/sleep disorders (10%)</p>
<p><b>Common</b> (1% to 10%): Depression, anxiety, sleep disorders, insomnia, abnormal dreams</p>
<p><b>Frequency not reported</b>: Mania, worsening of preexisting depression, lethargy<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal bilirubin</p>
<p><b>Frequency not reported</b>: Increased GGT, severe hepatomegaly with steatosis</p>
<p><b>Postmarketing reports</b>: Hepatic steatosis<sup>[Ref]</sup></p><p>Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have been reported in 6% and up to 6% of patients, respectively.</p>
<p></p>
<p>The reported frequencies were similar to those observed during clinical trials with zidovudine and lamivudine administration.</p>
<p></p>
<p>Increased GGT was observed in the expanded access program.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Neutropenia, thrombocytopenia, decreased white cells, abnormal absolute neutrophils</p>
<p><b>Uncommon</b> (0.1% to 1%): Anemia, leukopenia, abnormal hemoglobin, abnormal platelets, abnormal WBC</p>
<p><b>Rare</b> (less than 0.1%): Eosinophilia</p>
<p><b>Frequency not reported</b>: Agranulocytosis, increased platelet reactivity<sup>[Ref]</sup></p><p>Neutropenia (absolute neutrophil count less than 750/mm3), thrombocytopenia (platelets less than 50,000/mm3), anemia (hemoglobin 6.9 g/dL or less), and leukopenia (WBC 1500/mm3 or less) have been reported in up to 5%, 1%, less than 1%, and less than 1% of patients, respectively.</p>
<p></p>
<p>The reported frequencies were similar to those observed during clinical trials with zidovudine and lamivudine administration.</p>
<p></p>
<p>Agranulocytosis has been reported after the addition of this drug to a multi-drug regimen.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Renal signs/symptoms, abnormal creatinine</p>
<p><b>Frequency not reported</b>: Acute renal failure, interstitial nephritis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)</p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Endothelial dysfunction, peripheral arterial disease, coronary bypass surgery, ischemic stroke, deep venous thrombosis, angina, transient ischemic attack</p>
<p><b>Postmarketing reports</b>: Myocardial infarction (MI)<sup>[Ref]</sup></p><p>An observational study investigating the rate of MI in patients on combination antiretroviral therapy showed an increased risk of MI with the use of this drug within the previous 6 months.  A sponsor-conducted pooled analysis of clinical trials showed no excess risk of MI in abacavir-treated patients as compared with control subjects.  Overall, available data from the observational cohort and from clinical trials were inconclusive.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. AIDSinfo. NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2015 Mar 5]):</p><p id="ref_2">2. Calza L,  Dentale N,  Piergentili B, et al. "Abacavir-induced febrile agranulocytosis and anaemia." AIDS 22 (2008): 2221-2</p><p id="ref_3">3. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_6">6. "Product Information. Ziagen (abacavir)." Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_7">7. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2015 Apr 8]):</p><p id="ref_8">8. Bart PA, Rizzardi GP, Tambussi G, Chave JP, Chapuis AG, Graziois C, Corpataux JM, Halkic N, Meuwly JY, Munoz M, Meylan P, "Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy." Aids 14 (2000): 1887-97</p><p id="ref_9">9. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_10">10. Peyriere H,  Dereure O,  Breton H, et al. "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?" Br J Dermatol 155 (2006): 422-8</p><p id="ref_11">11. Hetherington S,  McGuirk S,  Powell G, et al. "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir." Clin Ther 23 (2001): 1603-14</p><p id="ref_12">12. Waters LJ,  Mandalia S,  Gazzard B,  Nelson M "Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience." AIDS 21 (2007): 2533-2534</p><p id="ref_13">13. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8</p><p id="ref_14">14. Abel S,  Paturel L,  Cabie A "Abacavir hypersensitivity." N Engl J Med 358 (2008): 2515; author reply 2515-6</p><p id="ref_15">15. Cutrell AG,  Hernandez JE,  Fleming JW, et al. "Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir." Ann Pharmacother 38 (2004): 2171-2</p><p id="ref_16">16. Strategies for Management of Anti-RetroviralTherapy/Insight; DAD Study Groups "Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients." AIDS 22 (2008): F17-F24</p><p id="ref_17">17. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_18">18. Chen SJ,  Yang SP,  Hung CC,  Fung CP "Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative." AIDS 24 (2010): 1238-9</p><p id="ref_19">19. Toerner JG,  Cvetkovich T "Kawasaki-like Syndrome: Abacavir Hypersensitivity?" Clin Infect Dis 34 (2002): 131-2</p><p id="ref_20">20. Yokogawa N,  Alcid DV "Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction." AIDS 21 (2007): 2116-2117</p><p id="ref_21">21. Fox J,  Newton P,  Daly R, et al. "An unusual abacavir reaction." AIDS 22 (2008): 1520-2</p><p id="ref_22">22. Phillips EJ "Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?" Clin Infect Dis 43 (2006): 103-5</p><p id="ref_23">23. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><p id="ref_24">24. Bonta PI,  Vermeulen JN,  Speelman P,  Prins JM "Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative." AIDS 22 (2008): 1522-3</p><p id="ref_25">25. de Perio MA,  Gomez FJ,  Frame PT,  Fichtenbaum CJ "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS 21 (2007): 2252-3</p><p id="ref_26">26. Yuen GJ,  Weller S,  Pakes GE "A Review of the Pharmacokinetics of Abacavir." Clin Pharmacokinet 47 (2008): 351-371</p><p id="ref_27">27. Fontaine C,  Guiard-Schmid JB,  Slama L, et al. "Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate." AIDS 19 (2005): 1927-8</p><p id="ref_28">28. Loeliger AE, Steel H, McGuirk S, Powell WS, Hetherington SV "The abacavir hypersensitivity reaction and interruptions in therapy." Aids 15 (2001): 1325</p><p id="ref_29">29. Herring SJ,  Krieger AC "Acute respiratory manifestations of the abacavir hypersensitivity reaction." AIDS 20 (2006): 301-2</p><p id="ref_30">30. Rauch A,  Nolan D,  Martin A,  McKinnon E,  Almeida C,  Mallal S "Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study." Clin Infect Dis 43 (2006): 99-102</p><p id="ref_31">31. Hughes CA,  Foisy MM,  Dewhurst N, et al. "Abacavir hypersensitivity reaction: an update." Ann Pharmacother 42 (2008): 387-96</p><p id="ref_32">32. Hervey PS, Perry CM "Abacavir - A review of its clinical potential in patients with HIV infection." Drugs 60 (2000): 447-79</p><p id="ref_33">33. Hammer SM,  Saag MS,  Schechter M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA 296 (2006): 827-43</p><p id="ref_34">34. Tozzi V "Pharmacogenetics of antiretrovirals." Antiviral Res 85 (2010): 190-200</p><p id="ref_35">35. Goedken AM,  Herman RA "Once-daily abacavir in place of twice-daily administration." Ann Pharmacother 39 (2005): 1302-8</p><p id="ref_36">36. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_37">37. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70</p><p id="ref_38">38. Stekler J,  Maenza J,  Stevens C, et al. "Abacavir hypersensitivity reaction in primary HIV infection." AIDS 20 (2006): 1269-74</p><p id="ref_39">39. Vandekerckhove L,  Blot S "Abacavir hypersensitivity." N Engl J Med 358 (2008): 2514-5; author reply 2515-6</p><p id="ref_40">40. Barber TJ,  Marett B,  Waldron S, et al. "Are disulfiram-like reactions associated with abacavir-containing antiretroviral  regimens in clinical practice?" AIDS 21 (2007): 1823-1824</p><p id="ref_41">41. Del Giudice P,  Vandenbos F,  Perrin C,  Bernard E,  Marq L,  Dellamonica P "Sweet's syndrome following abacavir therapy." J Am Acad Dermatol 51 (2004): 474-5</p><p id="ref_42">42. Larios OE,  Kasper K,  Becker ML "First report of abacavir associated with hypoglycemia." AIDS 24 (2010): 2138-9</p><p id="ref_43">43. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89</p><p id="ref_44">44. Soni S,  Churchill DR,  Gilleece Y "Abacavir-induced hepatotoxicity: a report of two cases." AIDS 22 (2008): 2557-8</p><p id="ref_45">45. Sankatsing SU,  Prins JM "Agranulocytosis and fever seven weeks after starting abacavir." AIDS 15 (2001): 2464-5</p><p id="ref_46">46. Satchell CS,  O'Halloran JA,  Cotter AG, et al. "Increased Platelet Reactivity in HIV-1-Infected Patients Receiving Abacavir-Containing Antiretroviral Therapy." J Infect Dis 204 (2011): 1202-10</p><p id="ref_47">47. Hsue PY,  Hunt PW,  Wu Y, et al. "Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients." AIDS 23 (2009): 2021-7</p><p id="ref_48">48. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p><p id="ref_49">49. Bedimo RJ,  Westfall AO,  Drechsler H,  Vidiella G,  Tebas P "Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era." Clin Infect Dis 53 (2011): 84-91</p><p id="ref_50">50. Cruciani M,  Zanichelli V,  Serpelloni G, et al. "ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data." AIDS 25 (2011): 1993-2004</p><p id="ref_51">51. Calza L,  Manfredi R,  Verucchi G "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis,  and clinical management." AIDS 24 (2010): 789-802</p><p id="ref_52">52. Ribaudo HJ,  Benson CA,  Zheng Y, et al. "No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT." Clin Infect Dis 52 (2011): 929-940</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Ziagen (abacavir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Generic Availability</li>
<li>Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)</li>
<li>FDA Alerts (5)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ziagen &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to abacavir: oral solution, oral tablet</i></p><h3>General</h3><p>In 1 study, patients receiving the once-daily regimen had a significantly higher incidence of severe drug hypersensitivity reactions and severe diarrhea than patients on the twice-daily regimen.</p><p></p><p>Many of the side effects listed occurred commonly in patients with abacavir (the active ingredient contained in Ziagen) hypersensitivity (e.g., nausea, vomiting, diarrhea, fever, lethargy, rash).<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity, hypersensitivity reaction (including fever, rash [maculopapular, urticarial], nausea, vomiting, malaise, diarrhea, headache, fatigue, myalgia, achiness, abdominal pain, pharyngitis, dyspnea, cough, lethargy, myolysis, edema, elevated liver function tests, mucous membrane lesions [conjunctivitis, mouth ulceration], sore throat, adult respiratory distress syndrome, respiratory failure, lymphadenopathy, hypotension, anaphylaxis, paresthesia, lymphopenia, hepatitis, liver failure, arthralgia, elevated creatine phosphokinase, elevated creatinine, renal failure, erythema multiforme, abnormal chest x-ray findings [mainly localized infiltrates], death)</p><p><b>Frequency not reported</b>: Serious and sometimes fatal hypersensitivity reactions, abacavir (the active ingredient contained in Ziagen) hypersensitivity reaction presenting as acute fibrinous and organizing pneumonia<sup>[Ref]</sup></p><p>Serious and sometimes fatal hypersensitivity reactions have been reported with this drug.  Such reactions have included multi-organ failure and anaphylaxis and usually occurred within the first 6 weeks of therapy (median onset: 9 to 11 days); however, abacavir hypersensitivity reactions have occurred any time during therapy.</p><p></p><p>Patients with the human leukocyte antigen subtype B*5701 (HLA-B*5701) allele are at higher risk of hypersensitivity reactions to this drug; however, such reactions have occurred in patients without the HLA-B*5701 allele.  Abacavir hypersensitivity was reported in about 8% of patients in 9 clinical trials with abacavir-containing products where patients were not screened for the HLA-B*5701 allele; incidence of suspected abacavir hypersensitivity reactions was 1% in clinical trials where HLA-B*5701 carriers were excluded.</p><p></p><p>Abacavir hypersensitivity reactions have been characterized by at least 2 of the following key signs/symptoms: (1) fever; (2) rash; (3) gastrointestinal symptoms (including nausea, vomiting, diarrhea, abdominal pain); (4) constitutional symptoms (including generalized malaise, fatigue, achiness); (5) respiratory symptoms (including dyspnea, cough, pharyngitis).  Almost all reactions have included fever and/or rash (usually maculopapular or urticarial); however, reactions also reported without fever or rash.  Signs/symptoms reported in at least 10% of patients with hypersensitivity reaction have included rash, nausea, vomiting, malaise, diarrhea, headache, fatigue/lethargy, abdominal pain, dyspnea, cough, fever, elevated liver function tests, and myalgia.  Other signs/symptoms of hypersensitivity have included mouth ulceration, sore throat, adult respiratory distress syndrome, respiratory failure, edema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, paresthesia, lymphopenia, hepatitis, liver failure, myolysis, arthralgia, elevated creatine phosphokinase, elevated creatinine, renal failure, abnormal chest x-ray findings (mainly infiltrates, which were localized), and death.</p><p></p><p>Symptoms of abacavir hypersensitivity reaction worsened with continued therapy and generally resolved when this drug was discontinued.  Restarting this drug after a hypersensitivity reaction has resulted in more severe symptoms within hours and included life-threatening hypotension and death.  Rarely, life-threatening reactions have occurred within hours after restarting this drug in patients who stopped it for reasons other than symptoms of hypersensitivity (or who stopped it with only 1 key symptom of hypersensitivity).</p><p></p><p>In 1 case report, a 57-year-old HIV-positive male presented to medical attention with a 2-day history of fever, malaise, and diarrhea related to initiation of this drug.  Six days prior to the onset of symptoms, the patient's antiretroviral therapy was switched from efavirenz and lamivudine-zidovudine to zidovudine, abacavir, and lopinavir-ritonavir after a drop in his CD4 cell count.  The patient developed acute dyspnea and severe hypoxemia, hemoptysis, and diffuse bilateral pulmonary infiltrates within 72 hours of admission and this drug was discontinued due to suspicion of a hypersensitivity reaction.  Three days after drug discontinuation, the patient's status improved and chest films showed resolution of infiltrates.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Pancreatitis was observed in the expanded access program.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 47%), nausea and vomiting (up to 38%), diarrhea (up to 16%)</p><p><b>Common</b> (1% to 10%): Abdominal pain/gastritis/gastrointestinal signs and symptoms, vomiting, abdominal discomfort and pain, abnormal amylase</p><p><b>Rare</b> (0.01% to 0.1%): Pancreatitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Malaise and fatigue (up to 34%), temperature regulation disturbance (up to 19%)</p><p><b>Common</b> (1% to 10%): Fever/pyrexia, lethargy, fatigue, fatigue/malaise, fever and/or chills</p><p><b>Uncommon</b> (0.1% to 1%): Non-site-specific pain</p><p><b>Frequency not reported</b>: Asthenia, reduced alcohol tolerance, disulfiram-like reaction<sup>[Ref]</sup></p><p>In 1 case report, a 31-year-old HIV-infected male patient switched to this drug and experienced a disulfiram-like reaction with nausea, facial flushing, and tachycardia after alcohol consumption.  When the patient was rechallenged with a shot of vodka, the same reaction occurred.</p><p></p><p>In another case, a 27-year-old HIV-infected male patient switched to this drug and noticed reduced alcohol tolerance.  The patient reported that he felt as if he had ingested 1.5 bottles of wine after 3 glasses, with loss of memory until the next morning and vomiting.  The patient was able to tolerate small quantities of alcohol or alcohol consumed with food.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 31%)</p><p><b>Common</b> (1% to 10%): Headaches/migraine, dizziness, neuropathy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 24%), ear/nose/throat infections (up to 19%), nasal signs/symptoms (up to 11%)</p><p><b>Common</b> (1% to 10%): Viral respiratory infections (including viral ear, nose, and throat infection), bronchitis</p><p><b>Frequency not reported</b>: Tachypnea, pharyngitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Elevated creatine phosphokinase (greater than 4 times the upper limit of normal [4 x ULN]) has been reported in up to 8% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated creatine phosphokinase (up to 12%)</p><p><b>Common</b> (1% to 10%): Musculoskeletal pain</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Osteonecrosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Suspected Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported during postmarketing experience in patients using this drug primarily in combination with agents known to be associated with SJS and TEN, respectively.</p><p></p><p>Cases of erythema multiforme, SJS, or TEN have been reported very rarely when abacavir (the active ingredient contained in Ziagen) hypersensitivity could not be ruled out.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Skin rashes (maculopapular, urticarial, or variable appearance; up to 11%)</p><p><b>Common</b> (1% to 10%): Rash (without systemic symptoms)</p><p><b>Frequency not reported</b>: Sweet's syndrome</p><p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hypertriglyceridemia (greater than 750 mg/dL), hyperamylasemia (greater than 2 x ULN), and hyperglycemia (greater than 13.9 mmol/L) have been reported in up to 6%, up to 4%, and less than 1% of patients, respectively.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Feeding problems (up to 11%)</p><p><b>Common</b> (1% to 10%): Hypertriglyceridemia, hyperamylasemia, anorexia, abnormal triglycerides, hyperlactatemia</p><p><b>Uncommon</b> (0.1% to 1%): Hyperglycemia, abnormal alkaline phosphatase, abnormal glucose, abnormal sodium</p><p><b>Rare</b> (0.01% to 0.1%): Lactic acidosis</p><p><b>Frequency not reported</b>: Mild elevations of blood glucose, hypoglycemia, loss of appetite</p><p><b>Postmarketing reports</b>: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Metabolic abnormalities (e.g., hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Dreams/sleep disorders (10%)</p><p><b>Common</b> (1% to 10%): Depression, anxiety, sleep disorders, insomnia, abnormal dreams</p><p><b>Frequency not reported</b>: Mania, worsening of preexisting depression, lethargy<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal bilirubin</p><p><b>Frequency not reported</b>: Increased GGT, severe hepatomegaly with steatosis</p><p><b>Postmarketing reports</b>: Hepatic steatosis<sup>[Ref]</sup></p><p>Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have been reported in 6% and up to 6% of patients, respectively.</p><p></p><p>The reported frequencies were similar to those observed during clinical trials with zidovudine and lamivudine administration.</p><p></p><p>Increased GGT was observed in the expanded access program.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Neutropenia, thrombocytopenia, decreased white cells, abnormal absolute neutrophils</p><p><b>Uncommon</b> (0.1% to 1%): Anemia, leukopenia, abnormal hemoglobin, abnormal platelets, abnormal WBC</p><p><b>Rare</b> (less than 0.1%): Eosinophilia</p><p><b>Frequency not reported</b>: Agranulocytosis, increased platelet reactivity<sup>[Ref]</sup></p><p>Neutropenia (absolute neutrophil count less than 750/mm3), thrombocytopenia (platelets less than 50,000/mm3), anemia (hemoglobin 6.9 g/dL or less), and leukopenia (WBC 1500/mm3 or less) have been reported in up to 5%, 1%, less than 1%, and less than 1% of patients, respectively.</p><p></p><p>The reported frequencies were similar to those observed during clinical trials with zidovudine and lamivudine administration.</p><p></p><p>Agranulocytosis has been reported after the addition of this drug to a multi-drug regimen.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Renal signs/symptoms, abnormal creatinine</p><p><b>Frequency not reported</b>: Acute renal failure, interstitial nephritis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)</p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Endothelial dysfunction, peripheral arterial disease, coronary bypass surgery, ischemic stroke, deep venous thrombosis, angina, transient ischemic attack</p><p><b>Postmarketing reports</b>: Myocardial infarction (MI)<sup>[Ref]</sup></p><p>An observational study investigating the rate of MI in patients on combination antiretroviral therapy showed an increased risk of MI with the use of this drug within the previous 6 months.  A sponsor-conducted pooled analysis of clinical trials showed no excess risk of MI in abacavir-treated patients as compared with control subjects.  Overall, available data from the observational cohort and from clinical trials were inconclusive.<sup>[Ref]</sup></p><p id="ref_1">1. AIDSinfo. NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2015 Mar 5]):</p><p id="ref_2">2. Calza L,  Dentale N,  Piergentili B, et al. "Abacavir-induced febrile agranulocytosis and anaemia." AIDS 22 (2008): 2221-2</p><p id="ref_3">3. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_6">6. "Product Information. Ziagen (abacavir)." Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_7">7. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2015 Apr 8]):</p><p id="ref_8">8. Bart PA, Rizzardi GP, Tambussi G, Chave JP, Chapuis AG, Graziois C, Corpataux JM, Halkic N, Meuwly JY, Munoz M, Meylan P, "Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy." Aids 14 (2000): 1887-97</p><p id="ref_9">9. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_10">10. Peyriere H,  Dereure O,  Breton H, et al. "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?" Br J Dermatol 155 (2006): 422-8</p><p id="ref_11">11. Hetherington S,  McGuirk S,  Powell G, et al. "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir." Clin Ther 23 (2001): 1603-14</p><p id="ref_12">12. Waters LJ,  Mandalia S,  Gazzard B,  Nelson M "Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience." AIDS 21 (2007): 2533-2534</p><p id="ref_13">13. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8</p><p id="ref_14">14. Abel S,  Paturel L,  Cabie A "Abacavir hypersensitivity." N Engl J Med 358 (2008): 2515; author reply 2515-6</p><p id="ref_15">15. Cutrell AG,  Hernandez JE,  Fleming JW, et al. "Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir." Ann Pharmacother 38 (2004): 2171-2</p><p id="ref_16">16. Strategies for Management of Anti-RetroviralTherapy/Insight; DAD Study Groups "Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients." AIDS 22 (2008): F17-F24</p><p id="ref_17">17. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_18">18. Chen SJ,  Yang SP,  Hung CC,  Fung CP "Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative." AIDS 24 (2010): 1238-9</p><p id="ref_19">19. Toerner JG,  Cvetkovich T "Kawasaki-like Syndrome: Abacavir Hypersensitivity?" Clin Infect Dis 34 (2002): 131-2</p><p id="ref_20">20. Yokogawa N,  Alcid DV "Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction." AIDS 21 (2007): 2116-2117</p><p id="ref_21">21. Fox J,  Newton P,  Daly R, et al. "An unusual abacavir reaction." AIDS 22 (2008): 1520-2</p><p id="ref_22">22. Phillips EJ "Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?" Clin Infect Dis 43 (2006): 103-5</p><p id="ref_23">23. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><p id="ref_24">24. Bonta PI,  Vermeulen JN,  Speelman P,  Prins JM "Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative." AIDS 22 (2008): 1522-3</p><p id="ref_25">25. de Perio MA,  Gomez FJ,  Frame PT,  Fichtenbaum CJ "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS 21 (2007): 2252-3</p><p id="ref_26">26. Yuen GJ,  Weller S,  Pakes GE "A Review of the Pharmacokinetics of Abacavir." Clin Pharmacokinet 47 (2008): 351-371</p><p id="ref_27">27. Fontaine C,  Guiard-Schmid JB,  Slama L, et al. "Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate." AIDS 19 (2005): 1927-8</p><p id="ref_28">28. Loeliger AE, Steel H, McGuirk S, Powell WS, Hetherington SV "The abacavir hypersensitivity reaction and interruptions in therapy." Aids 15 (2001): 1325</p><p id="ref_29">29. Herring SJ,  Krieger AC "Acute respiratory manifestations of the abacavir hypersensitivity reaction." AIDS 20 (2006): 301-2</p><p id="ref_30">30. Rauch A,  Nolan D,  Martin A,  McKinnon E,  Almeida C,  Mallal S "Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study." Clin Infect Dis 43 (2006): 99-102</p><p id="ref_31">31. Hughes CA,  Foisy MM,  Dewhurst N, et al. "Abacavir hypersensitivity reaction: an update." Ann Pharmacother 42 (2008): 387-96</p><p id="ref_32">32. Hervey PS, Perry CM "Abacavir - A review of its clinical potential in patients with HIV infection." Drugs 60 (2000): 447-79</p><p id="ref_33">33. Hammer SM,  Saag MS,  Schechter M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA 296 (2006): 827-43</p><p id="ref_34">34. Tozzi V "Pharmacogenetics of antiretrovirals." Antiviral Res 85 (2010): 190-200</p><p id="ref_35">35. Goedken AM,  Herman RA "Once-daily abacavir in place of twice-daily administration." Ann Pharmacother 39 (2005): 1302-8</p><p id="ref_36">36. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_37">37. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70</p><p id="ref_38">38. Stekler J,  Maenza J,  Stevens C, et al. "Abacavir hypersensitivity reaction in primary HIV infection." AIDS 20 (2006): 1269-74</p><p id="ref_39">39. Vandekerckhove L,  Blot S "Abacavir hypersensitivity." N Engl J Med 358 (2008): 2514-5; author reply 2515-6</p><p id="ref_40">40. Barber TJ,  Marett B,  Waldron S, et al. "Are disulfiram-like reactions associated with abacavir-containing antiretroviral  regimens in clinical practice?" AIDS 21 (2007): 1823-1824</p><p id="ref_41">41. Del Giudice P,  Vandenbos F,  Perrin C,  Bernard E,  Marq L,  Dellamonica P "Sweet's syndrome following abacavir therapy." J Am Acad Dermatol 51 (2004): 474-5</p><p id="ref_42">42. Larios OE,  Kasper K,  Becker ML "First report of abacavir associated with hypoglycemia." AIDS 24 (2010): 2138-9</p><p id="ref_43">43. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89</p><p id="ref_44">44. Soni S,  Churchill DR,  Gilleece Y "Abacavir-induced hepatotoxicity: a report of two cases." AIDS 22 (2008): 2557-8</p><p id="ref_45">45. Sankatsing SU,  Prins JM "Agranulocytosis and fever seven weeks after starting abacavir." AIDS 15 (2001): 2464-5</p><p id="ref_46">46. Satchell CS,  O'Halloran JA,  Cotter AG, et al. "Increased Platelet Reactivity in HIV-1-Infected Patients Receiving Abacavir-Containing Antiretroviral Therapy." J Infect Dis 204 (2011): 1202-10</p><p id="ref_47">47. Hsue PY,  Hunt PW,  Wu Y, et al. "Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients." AIDS 23 (2009): 2021-7</p><p id="ref_48">48. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p><p id="ref_49">49. Bedimo RJ,  Westfall AO,  Drechsler H,  Vidiella G,  Tebas P "Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era." Clin Infect Dis 53 (2011): 84-91</p><p id="ref_50">50. Cruciani M,  Zanichelli V,  Serpelloni G, et al. "ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data." AIDS 25 (2011): 1993-2004</p><p id="ref_51">51. Calza L,  Manfredi R,  Verucchi G "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis,  and clinical management." AIDS 24 (2010): 789-802</p><p id="ref_52">52. Ribaudo HJ,  Benson CA,  Zheng Y, et al. "No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT." Clin Infect Dis 52 (2011): 929-940</p><h2>More about Ziagen (abacavir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Generic Availability</li>
<li>Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)</li>
<li>FDA Alerts (5)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ziagen &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>